EUVIMEDEUVIMED entdecken
Open Access

Systematic characterization of antibody–drug conjugate targets in central nervous system tumors

Shannon Coy iD, Jong Suk Lee iD, Sabrina J Chan iD, Terri Woo, Jacquelyn Jones, Sanda Alexandrescu iD, Patrick Y Wen, Peter K Sorger iD, Keith L Ligon iD, Sandro Santagata iD

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Shannon Coy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunoconjugates, Breast Neoplasms, Central Nervous System Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibody–drug conjugates (ADCs) enhance the specificity of cytotoxic drugs by directing them to cells expressing target antigens. Multiple ADCs are FDA-approved for solid and hematologic malignancies, including those expressing HER2, TROP2, and NECTIN4. Recently, an ADC targeting HER2 (Trastuzumab-Deruxtecan) increased survival and reduced growth of brain metastases in treatment-refractory metastatic breast cancer, even in tumors with low HER2 expression. Thus, low-level expression of ADC targets may be sufficient for treatment responsiveness. However, ADC target expression is poorly characterized in many central nervous system (CNS) tumors.

Methods

We analyzed publicly available RNA-sequencing and proteomic data from the children’s brain tumor network (N = 188 tumors) and gene-expression-omnibus RNA-expression datasets (N = 356) to evaluate expression of 14 potential ADC targets that are FDA-approved or under investigation in solid cancers. We also used immunohistochemistry to measure the levels of HER2, HER3, NECTIN4, TROP2, CLDN6, CLDN18.2, and CD276/B7-H3 protein in glioblastoma, oligodendroglioma, meningioma, ependymoma, pilocytic astrocytoma, medulloblastoma, atypical teratoid/rhabdoid tumor (AT/RT), adamantinomatous craniopharyngioma (ACP), papillary craniopharyngioma (PCP), and primary CNS lymphoma (N = 575).

Results

Pan-CNS analysis showed subtype-specific expression of ADC target proteins. Most tumors expressed HER3, B7-H3, and NECTIN4. Ependymomas strongly expressed HER2, while meningiomas showed weak-moderate HER2 expression. ACP and PCP strongly expressed B7-H3, with TROP2 expression in whorled ACP epithelium. AT/RT strongly expressed CLDN6. Glioblastoma showed little subtype-specific marker expression, suggesting a need for further target development.

Conclusions

CNS tumors exhibit subtype-specific expression of ADC targets including several FDA-approved for other indications. Clinical trials of ADCs in CNS tumors may therefore be warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunoconjugatesBreast NeoplasmsCentral Nervous System NeoplasmsRhabdoid TumorCerebellar NeoplasmsChildHumansFemaleProteomicsRNAClaudinsB7 Antigens

Stichwörter der Autor:innen

craniopharyngiomaependymomagliomaimmunoconjugatesmeningioma

Substanzen

ImmunoconjugatesRNACLDN18 protein, humanClaudinsCD276 protein, humanB7 Antigens

Autor:innen und Institutionen

  • Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Boston, Massachusetts, USA.
  • Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, USA.
  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Shannon Coy, Jong Suk Lee, Sabrina J Chan, Sanda Alexandrescu, Peter K Sorger, Keith L Ligon, Sandro Santagata

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NIBIB NIH HHS
  • National Institutes of Health
  • Ludwig Center at Harvard
  • National Brain Tumor Society
  • Pediatric Brain Tumor Foundation
  • Accelerate Brain Cancer Cure

Zitieren

APA

Coy, S., Lee, J. S., Chan, S. J., Woo, T., Jones, J., Alexandrescu, S., Wen, P. Y., Sorger, P. K., Ligon, K. L., & Santagata, S. (2024). Systematic characterization of antibody–drug conjugate targets in central nervous system tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad205

Vancouver

Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, et al. Systematic characterization of antibody–drug conjugate targets in central nervous system tumors. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad205

BibTeX
@article{Coy2024,
  author = {Coy, Shannon and Lee, Jong Suk and Chan, Sabrina J and Woo, Terri and Jones, Jacquelyn and Alexandrescu, Sanda and Wen, Patrick Y and Sorger, Peter K and Ligon, Keith L and Santagata, Sandro},
  title = {Systematic characterization of antibody–drug conjugate targets in central nervous system tumors},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad205}
}
Kostenlos starten →